title: Expression IRF/MUM1>25% Predictor to Three-year Survival of Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era.
abstract: BACKGROUND
  Non Hodgkin lymphoma-Diffuse large B cell lymphoma (DLBC) is composed of more varieties of one disease. Analysis and understanding of a wide range of characteristics of the disease, which include: clinical, immunohistochemical, cytogenetic and molecular characteristics may improve treatment results.
  
  
  OBJECTIVE
  achieving the estimated three-year survival and influence of IRF/MUM1 expression to three-year survival.
  
  
  METHODS
  A study was retrospective-prospective, patients were followed for seven years a period of dine. The study included 60 patients de novo DLBCL. Age was 18-72 years old, the average age 45 years, male 31 (51,7%) and female 29 (48.3%). Median follow-up was 47 months (3-91 months). To determine differentiation immunophenotype antibodies those were used anti-CD20, anti-CD10, anti-Bcl-6, IRF-4/MUM1, CD 138.
  
  
  RESULTS
  Included the GCB type was 65%. Impact prognostic index IPI>2 GBC vs non GBC p=0,038 X2. Statistically significant difference was confirmed compared to the IPI> 2 to 3 year OS p<0,0005 X2. Significantly longer three-year survival was provided in the group GCB 36 (92,3%) vs. non GCB 8 (38,1%) p=0,003 X2. Clinical and immunohistochemical factors showed a significant impact to three-year survival by univariate: LDH p=0,005, MUM1 p=0,003, while CD10 p=0,069 was confirmed on the level of borderline impact. Using multivariate analysis, expression MUM1 has the greatest impact p<0.0005 OR=0.083 (95% CI 0.23-0.303) on the disease outcome - three-year survival.
  
  
  CONCLUSIONS
  expression MUM1 >25% has the greatest impact on the disease outcome - three-year survival.
authors.affiliation: Hematology Clinic of the Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
authors.forename: Alma
authors.initials: A
authors.lastname: Sofo-Hafizovic
authors.affiliation: Patology Institute of the Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
authors.forename: Adisa
authors.initials: A
authors.lastname: Chikha
authors.affiliation: Clinic for Infectious diseases of the Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
authors.forename: Refet
authors.initials: R
authors.lastname: Gojak
authors.affiliation: Hematology Clinic of the Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
authors.forename: Emina Suljovic
authors.initials: ES
authors.lastname: Hadzimesic
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007167:Immunotherapy; D050835:Interferon Regulatory Factors / Q000378:metabolism*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult; D000099218:Interferon Regulatory Factor-4
chemical_list: D050835:Interferon Regulatory Factors; D000099218:Interferon Regulatory Factor-4
keywords: DLBCL; MUM1 expression; three-year survival